The session was moderated by CHAI Rong, Presenter of Zhuhai Media Group. The panelists included ZHU Baoguo, Chairman of Liv zon Group; LU Ligong, Director of Zhuhai Municipal People's Hospital, WANG Su, Co-founder & vice president of Fitlens Vision; QIAN Xiaoxiao, Senior Director of Head of Strategy at AstraZeneca R&D China; ZHONG Weide, National Talent, Hundred Thousand Ten Thousand Talents Project and Vice-chairman of the Youth Committee of the Urology branch of the Chinese Medical Association, and LIU Yuting, BCG Partner. They discussed various topics related to biopharmaceuticals.
ZHU Baoguo believed that the current environment presents both great opportunities and challenges for healthcare companies. This includes not only pharmaceutical research and development but also the survival environment, development status, and how to cultivate medical talents, all of which are integrated into the concept of innovation. LU Liheng pointed out that China still has significant room for improvement in independently developing new drugs and medical devices. He hoped that more new technological innovations and transformations can be applied to the field of medicine. WANG Su stated that there is still progress to be made in China's cataract surgery penetration rate and myopia prevention and control. The main focus currently is the comprehensive upgrading and development of myopia and cataract treatment, which meets the demands of optometry. QIAN Xiaoxiao started with the topic of "differentiation of innovative drugs." She believes that differentiation in drug research and development has multiple levels. On one hand, it requires in-depth research on molecular and cellular mechanisms. On the other hand, it requires joint efforts from pharmaceutical companies, hospitals, and doctors to select the most suitable drugs for patients. ZHONG Weide introduced the future development of geriatric diseases and the transformation of traditional Chinese medicine. He pointed out that this field has received support from the capital market and grasping these directions will help with research, capital, and industrial breakthroughs. LIU Yuting emphasized the application of new concepts such as regenerative medicine and medical devices in biopharmaceutical innovation.
Currently, biopharmaceutical technology is receiving significant attention as an effective approach to safeguard human health. The field of biopharmaceuticals has achieved numerous innovative breakthroughs, and related industries are gradually taking a leading position in the global economy. Against this backdrop, the panelists expressed their expectations of "thoroughly tackling the challenges in the treatment of major diseases and providing better assurance for human health." They unanimously believed that with the cross-development of various life sciences and technologies, many new biopharmaceutical technologies will emerge. In order to promote the transformation of biopharmaceutical technology and the clustered development of the industry, proactive exploration of promotion measures is needed. Additionally, attention should be given to the development of talents in the biopharmaceutical field, nurturing more professionals to drive further advancements in the industry.
